India NCLT Insolvency Resolution Filings — October 08, 2026

NCLAT appeal filed Oct 8 against CIRP admission for ₹2.79 crore debt; hearing Oct 9 creates binary event; if successful, stock could recover 5-10% from current levels; if not, CIRP could trigger 20-30% downside

NCLAT interim relief granted Oct 7 allows rights issue to proceed; Master Restructuring Agreement signed with principal FC holding ~97% CoC voting share; rights issue launch Oct 9 with completion by Dec 31, 2026

NCLT sanctioned scheme of amalgamation of 2 wholly owned subsidiaries (Kilburn Chemicals, Meghmani Crop Nutrition) into parent; operational synergies expected but no financial details disclosed; neutral near-term impact

Board approved revised allottee list for preferential allotment of 94.81% post-allotment capital; third revision in 2 months (Aug 21, Sep 19, Oct 8) signals ongoing negotiations but also potential for equity infusion completion

Fifth CoC meeting e-voting concluded Oct 7; both Resolution Professional appointments rejected by CoC; continued deadlock extends CIRP timeline, increases liquidation risk

13th CoC meeting postponed from Oct 8 to Oct 12; procedural delay suggests no imminent resolution; company has been under CIRP since Feb 2024 (20+ months)

Rights issue process must start Oct 9 and conclude by Dec 31, 2026; tight 83-day timeline creates execution risk but also catalyst for debt reduction if successful

CIRP admission by NCLT Ahmedabad under Section 9 of IBC for operational debt; appeal filed same day; high-profile company with strong brand; market reaction likely overdone if NCLAT stays CIRP

NCLT Ahmedabad admitted CIRP petition for ₹2.79 crore debt; appeal hearing Oct 9; if NCLAT upholds order, IRP appointed, management control lost, stock could fall 20-30%

Fifth CoC meeting rejected both RP appointments; no resolution professional in place; CIRP process stalled; liquidation risk increases with each failed meeting

Under CIRP since Feb 2024 (20+ months); 13th CoC meeting postponed; no resolution plan in sight; extended timeline erodes asset value

Third revision of preferential allottee list in 2 months; 94.81% post-allotment capital to be issued; high dilution risk for existing shareholders; regulatory scrutiny possible

Rights issue must complete by Dec 31, 2026; only 83 days from Oct 9; any regulatory or market delay could derail restructuring plan; NCLAT hearing on Nov 16 adds uncertainty

CIRP admission for small debt (₹2.79 crore) raises governance questions; could impact supplier relationships and credit terms even if appeal succeeds

Scheme of amalgamation effective only after ROC filing; no timeline provided; integration risks for 2 subsidiaries into parent

Hearing Oct 9; if NCLAT stays CIRP, stock could rebound 5-10% in short term; strong brand and fundamentals make this a potential buying opportunity on weakness

Rights issue launch Oct 9 with completion by Dec 31; Master Restructuring Agreement with principal FC (97% CoC voting share) ensures support; potential for debt reduction and turnaround

Interim relief granted for rights issue, capital increase, and director/CS digital signature restoration; board empowered to act; next hearing Nov 16 provides clarity timeline

Scheme of amalgamation of 2 wholly owned subsidiaries into parent; operational efficiencies and cost savings expected; no financial details yet but potential for margin improvement

Preferential allotment of 94.81% post-allotment capital; if completed, could provide significant capital for turnaround; revised allottee list suggests active negotiations

CoC deadlock may force liquidation or attract new bidders; distressed asset play for investors with high risk appetite; paper sector cyclical recovery could improve valuations

13th CoC meeting on Oct 12; any resolution plan discussion could trigger positive movement; company has been under CIRP for 20+ months, overdue for resolution

2 of 6 filings (Polycab India, Astron Paper) involve Section 9 operational debt petitions; Polycab's case for ₹2.79 crore highlights how small debts can trigger CIRP for large companies, creating disproportionate market impact

2 companies (BGR Energy, Shree Rajeshwaranand) pursuing equity infusion/rights issue as resolution mechanism; contrasts with traditional debt restructuring; suggests promoters prefer dilution over asset sale

2 companies (Astron Paper, SKIL Infrastructure) show CoC meeting delays/rejections; Astron Paper's 5th meeting failure and SKIL's 13th meeting postponement indicate systemic issues in resolution process efficiency

2 filings (Polycab India, BGR Energy) involve NCLAT appeals; Polycab's Oct 9 hearing and BGR Energy's Nov 16 hearing create near-term binary events; NCLAT's role as arbiter of CIRP admissions is critical

BGR Energy's 83-day rights issue timeline and Shree Rajeshwaranand's multiple allottee revisions suggest market pressure to complete restructuring quickly; any delay increases liquidation risk

Oct 9, 2026; binary event for stock; if CIRP stayed, stock likely rebounds; if upheld, significant downside; watch for any settlement with Asier Metals Private Limited

Oct 9, 2026; start of 83-day rights issue process; success depends on existing shareholder participation; watch for subscription levels

Nov 16, 2026; next listing for interim relief confirmation; any adverse order could derail restructuring

In-principle listing approval sought from BSE for preferential allotment; approval timeline uncertain; watch for regulatory scrutiny given 94.81% dilution

Oct 12, 2026 at 12:00 PM; postponed from Oct 8; watch for any resolution plan discussion or timeline for resolution

After 5th meeting rejection of both RPs; watch for 6th CoC meeting notice or liquidation application by NCLT; any new resolution applicant interest

Scheme effective date depends on filing with ROC Ahmedabad; watch for announcement of effective date and timeline for amalgamation completion